Stem Cell Clinic

Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results

By Global News Feed

CANTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the three and nine months ended September 30, 2020.

Read more:
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results

Tricida Announces Third Quarter 2020 Financial Results

By Global News Feed

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today financial results for the three and nine months ended September 30, 2020 and provided an update on key initiatives.

Visit link:
Tricida Announces Third Quarter 2020 Financial Results

Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC

By Global News Feed

Sydney, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release                                                                                                                    

See the rest here:
Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC

Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit

By Global News Feed

CHATHAM, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will be an invited speaker at the 3rd Annual Neuropsychiatric Drug Development Summit being held virtually November 10-12, 2020.

See more here:
Tonix Pharmaceuticals to Present at 3rd Annual Neuropsychiatric Drug Development Summit

Surface Oncology to Present at the Cowen IO Next Summit

By Global News Feed

CAMBRIDGE, Mass, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in a fireside chat at the upcoming Cowen 4th Annual IO Next Summit on Friday, November 13, 2020 at 10:45 a.m. ET. The discussion will focus on Surface’s lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27).

Visit link:
Surface Oncology to Present at the Cowen IO Next Summit

→←